Interim analysis of ELEANOR (n=200): a multi-national; prospective; non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib.

Bartsch, R; Harbeck, N; Wrobel, D; Zaiss, M; Terhaag, J; Guth, D; Distelrath, A; Wuerstlein, R; Zahn, MO; Luftner, D; Schwitter, M; Balic, M; Jackisch, C; Muller, V; Rinnerthaler, G; Schmidt, M; Zaman, K; Schinkothe, T; Gorray, M; Breitenstein, U.

The Breast 62S1 (2023) S20–S21.